Abstract
This chapter describes trends in the prevalence and patterns of alcohol and illicit drug use. While methodological differences, imprecise estimates and lack of data preclude firm conclusions on the global situation and trends in substance use, the available data suggest that alcohol and illicit drug consumption varies widely between societies. Per capita alcohol consumption is highest in the European Union and lowest in the South-East Asian and Eastern Mediterranean regions. There is a general long-term trend towards harmonisation of alcohol consumption, with decreasing levels in regions with traditionally high levels and increasing levels in regions with low levels. Trend data from surveys showed an increase in heavy episodic drinking among pupils in many European countries in the past decade, especially among girls.
Prevalence rates of illicit drug use are generally lower in the European Union compared to the USA, Canada and Australia, for which most research data are available. However, there are large variations between EU countries. Cannabis is worldwide the most frequently used illicit drug. Prevalence rates among young people tend to stabilise or decline in the past years, after a general increasing trend in the 1990s. Annual cocaine prevalence is higher among the general population of the USA and Canada compared to Australia and the EU, while annual prevalence of ecstasy and amphetamine use is highest in Australia. Within Europe, cocaine generally dominates the stimulant markets in the Western and Southern regions, albeit restricted to a few large countries. Amphetamines are the main stimulants in North, Central and Eastern Europe. Injecting drug use increases the risk of transmission of blood-born infectious diseases, like HIV and hepatitis B and C. China, the USA and Russia have the largest numbers of drug injectors. In terms of (midpoint) prevalence, highest rates are found in Azerbaijan and lowest in Cambodia.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
For the EU, recent and more comparable figures are available from the Eurobarometer survey in 2006 [12]. This survey showed a last year prevalence of abstinence 25% (males 16%, females 32%) in the population of 15 years and above of the EU-25, with highest rates reported in Italy (40%), Hungary (38%), Portugal (37%) and Malta (35%), and lowest rates of abstinence in Denmark [13] and the Netherlands (10%). See also paragraph on binge drinking. Note, however, that precision of estimates owing to comparability of methods is partly offset by the fairly small sample (roughly 1,000 respondents per country, with some exceptions).
References
Leung KS, Cottler LB. Ecstasy and other club drugs: a review of recent epidemiologic studies. Curr Opin Psychiatry. 2008;21:234–41.
EMCDDA. Annual report: the state of the drugs problem in Europe. Lisbon: EMCDDA; 2009. p. 2009.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Selected Issue 2009: Polydrug use: patterns and responses. Luxembourg: Office for Official Publications of the European Communities; 2009.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA 2002: Selected issue: polydrug use. Lisbon: EMCDDA; 2002.
World Health Organization. Global status report on alcohol 2004. Geneva: WHO; 2004.
Anderson P, Baumberg B. Alcohol in Europe: a public health perspective: a report for the European Commission. London: Institute of Alcohol Studies; 2006.
Rehm J, Room R, Van den Brink W, Kraus L. Problematic drug use and drug use disorders in EU countries and Norway: an overview of the epidemiology. Eur Neuropsychopharmacol. 2005;15(4):389–97.
Bobak M, Room R, Pikhart H, Kubinova R, Malyutina S, Pajak A, et al. Contribution of drinking patterns to differences in rates of alcohol related problems between three urban populations. J Epidemiol Community Health. 2004;58(3):238–42.
Gmel G, Room R, Kuendig H, Kuntsche S. Detrimental drinking patterns: empirical validation of the pattern values score of the Global Burden of Disease 2000 study in 13 countries. J Subst Use. 2007;12:337–58.
Rehm J, Rehn N, Room R, Monteiro M, Gmel G, Jernigan D, et al. The global distribution of average volume of alcohol consumption and patterns of drinking. Eur Addict Res. 2003;9(4):147–56.
Rehm J, Room R, Monteiro M, Gmel G, Graham K, Rehn N, et al. Alcohol use. In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, editors. Comparative quantification of health risks global and regional burden of disease attributable to selected major risk factors. Geneva: WHO; 2004. p. 959–1108.
European Commission. Attitudes towards alcohol: special Eurobarometer 272. Brussel: European Commission; 2007.
Comminity Epidemiology Work Group. Epidemiologic Trends in Drug Abuse: Proceedings of the Community Epidemiology Work Group: Highlights and Executive Summary. Bethesda, MD: National Institute of Drug Abuse; 2008.
Neumark YD, Lopez-Quintero C, Grinshpoon A, Levinson D. Alcohol drinking patterns and prevalence of alcohol-abuse and dependence in the Israel National Health Survey. Isr J Psychiatry Relat Sci. 2007;44(2):126–35.
Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-Âanalysis of effects on lipids and haemostatic factors. BMJ. 1999;319(7224):1523–8.
Fillmore KM, Kerr WC, Stockwell T, Chikritzhs T, Bostrom A. Moderate alcohol use and reduced mortality risk: systematic error in prospective studies. Addict Res Theory. 2006;14:101–32.
Lauer MS, Sorlie P. Alcohol, cardiovascular disease, and cancer: treat with caution. J Natl Cancer Inst. 2009;101(5):282–3.
Greenfield TK. Individual risk of alcohol-related disease and problems. In: Heather N, Peters T, Stockwell T, editors. International handbook of alcohol dependence and problems. New York: Wiley; 2001. p. 413–37.
Sundell L, Salomaa V, Vartiainen E, Poikolainen K, Laatikainen T. Increased stroke risk is related to a binge-drinking habit. Stroke. 2008;39(12):3179–84.
Deutsche Hauptstelle für Suchtfragen e.V.(DHS). Binge drinking and Europe. Hamm: DHS; 2008.
Naimi TS, Brewer RD, Mokdad A, Denny C, Serdula MK, Marks JS. Binge drinking among US adults. JAMA. 2003;289(1):70–5.
AIHW. National drug strategy household survey: detailed findings. Canberra: AIHW; 2007. p. 2008.
Clark DB, Thatcher DL, Tapert SF. Alcohol, psychological dysregulation, and adolescent brain development. Alcohol Clin Exp Res. 2008;32:375–85.
Hibell B, Guttormsson U, Ahlström S, Balakireva O, Bjarnason T, Kokkevi A, et al. The 2007 ESPAD report: substance use among students in 35 European countries. Stockholm: CAN; 2009.
Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the future: national results on adolescent drug use: overview of key findings, 2008. Bethesda, MD: National Institute on Drug Abuse; 2009.
Hasin D. Classification of alcohol use disorders. Alcohol Res Health. 2003;27(1):5–17.
De Graaf R, Bijl RV, Smit F, Vollebergh WA, Spijker J. Risk factors for 12-month comorbidity of mood, anxiety, and substance use disorders: findings from the Netherlands Mental Health Survey and Incidence Study. Am J Psychiatry. 2002;159(4):620–9.
Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64(7):830–42.
Grant BF. Toward an alcohol treatment model: a comparison of treated and untreated respondents with DSM-IV alcohol use disorders in the general population. Alcohol Clin Exp Res. 1996;20(2):372–8.
Grant BF, Compton WM, Crowley TJ, Hasin DS, Helzer JE, Li TK, et al. Errors in assessing DSM-IV substance use disorders. Arch Gen Psychiatry. 2007;64:379–80.
Cottler LB. Drug use disorders in the National Comorbidity Survey: have we come a long way? Arch Gen Psychiatry. 2007;64:380–1.
Kessler RC, Merikangas KR. Drug use disorders in the National Comorbidity Survey: have we come a long way? In reply. Arch Gen Psychiatry. 2007;64:381–2.
Kessler RC, Üstün TB. The WHO world mental health surveys: global perspectives on the epidemiology of mental disorders. New York: Cambridge University Press; 2008.
Oakley Browne MA, Wells JE, Scott KM. Te Rau Hinengaro: the New Zealand Mental Health Survey. Wellington: Ministry of Health; 2006.
Bromet EJ, Gluzman SF, Paniotto VI, Webb CP, Tintle NL, Zakhozha V, et al. Epidemiology of psychiatric and alcohol disorders in Ukraine: findings from the Ukraine World Mental Health survey. Soc Psychiatry Psychiatr Epidemiol. 2005;40(9):681–90.
Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:21–7.
Keyes KM, Grant BF, Hasin DS. Evidence for a closing gender gap in alcohol use, abuse, and dependence in the United States population. Drug Alcohol Depend. 2008;93(1–2):21–9.
Dick DM, Bierut LJ. The genetics of alcohol dependence. Curr Psychiatry Rep. 2006;8(2):151–7.
Sher KJ, Grekin ER, Williams NA. The development of alcohol use disorders. Annu Rev Clin Psychol. 2005;1:493–523.
United Nations Office On Drugs and Crime (UNODC). World Drug Report: 2009. Vienna: UNODC; 2009.
Adlaf EM, Begin P, Sawka E. Canadian Addiction Survey (CAS): a national survey of Canadians’ use of alcohol and other drugs: Prevalence of use and related harms: Detailed report. Ottawa: Canadian Centre on Substance Abuse; 2005.
SAMHSA. Results from the 2007 National Survey on Drug Use and Health: National findings. Rockville, MD: Office of Applied Studies; 2008.
Degenhardt L, Chiu WT, Sampson N, Kessler RC, Anthony JC, Angermeyer M, et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med. 2008;5(7):e141.
Furr-Holden CD, Anthony JC. Epidemiologic differences in drug dependence–a US-UK cross-national comparison. Soc Psychiatry Psychiatr Epidemiol. 2003;38(4):165–72.
Kilmer B. Do cannabis possession laws influence cannabis use? In: Spruit IP, editor. Cannabis 2002 report: a joint international effort at the initiative of the Ministers of Public Health of Belgium, France, Germany, The Netherlands, Switserland: technical report of the International Scientific Conference Brussels, Belgium, 25-02-2002. Brussels, Belgium: Ministry of Public Health; 2002. p. 119–42.
Simons-Morton B, Pickett W, Boyce W, Ter Bogt TF, Vollebergh W. Cross-national comparison of adolescent drinking and cannabis use in the United States, Canada, and the Netherlands. Int J Drug Policy. 2010;21(1):64–9.
EMCDDA. Annual report 2008: the state of the drugs problem in Europe. Lisbon: EMCDDA; 2008.
Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212–3.
Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction. 2004;99(10):1333–41.
Fergusson DM, Horwood LJ, Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction. 2002;97(9):1123–35.
Lynskey MT, Heath AC, Bucholz KK, Slutske WS, Madden PA, Nelson EC, et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA. 2003;289(4):427–33.
DeWit DJ, Offord DR, Wong M. Patterns of onset and cessation of drug use over the early part of the life course. Health Educ Behav. 1997;24(6):746–58.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). A cannabis reader: global issues and local experiences: perspectives on cannabis controversies, treatment and regulation in Europe, vol. 1. Lisbon: EMCDDA; 2008.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). A cannabis reader: global issues and local experiences: perspectives on cannabis controversies, treatment and regulation in Europe, vol. 2. Lisbon: EMCDDA; 2008.
Australian Institute of Health and Welfare. 2007 National Drug Strategy Household Survey: first results. Canberra: AIHW; 2008.
Currie C, Gabhainn SN, Godeau E, Roberts C, Smith R, Currie D, et al. Inequalities in young people’s health: HBSC international report from the 2005/2006 survey. Copenhagen: World Health Organisation, Europe; 2008.
Chen K, Kandel DB, Davies M. Relationships between frequency and quantity of marijuana use and last year proxy dependence among adolescents and adults in the United States. Drug Alcohol Depend. 1997;46(1–2):53–67.
Copersino ML, Boyd SJ, Tashkin DP, Huestis MA, Heishman SJ, Dermand JC, et al. Quitting among non-treatment-seeking marijuana users: reasons and changes in other substance use. Am J Addict. 2006;15(4):297–302.
Chen CY, O’Brien MS, Anthony JC. Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000-2001. Drug Alcohol Depend. 2005;79(1):11–22.
Coffey C, Carlin JB, Lynskey M, Li N, Patton GC. Adolescent precursors of cannabis dependence: findings from the Victorian Adolescent Health Cohort Study. Br J Psychiatry. 2003;182:330–6.
Von Sydow K, Lieb R, Pfister H, Hofler M, Wittchen HU. What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. Drug Alcohol Depend. 2002;68(1):49–64.
Korf DJ, Benschop A, Wouters M. Differential responses to cannabis potency: a typology of users based on self-reported consumption behaviour. Int J Drug Policy. 2007;18(3):168–76.
Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS. Prevalence of marijuana use disorders in the United States: 1991–1992 and 2001–2002. JAMA. 2004;291(17):2114–21.
Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med. 2006;36(10):1447–60.
Swift W, Hall W, Teesson M. Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Addiction. 2001;96(5):737–48.
Perkonigg A, Goodwin RD, Fiedler A, Behrendt S, Beesdo K, Lieb R, et al. The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction. 2008;103(3):439–49.
Boden JM, Fergusson DM, Horwood LJ. Illicit drug use and dependence in a New Zealand birth cohort. Aust NZ J Psychiatry. 2006;40(2):156–63.
Van Laar M, Cruts G, Van Gageldonk A, Croes E, Van Ooyen-Houben M, Meijer R, et al. Drug situation 2006 the Netherlands: report to the EMCDDA. Utrecht: Trimbos Institute; 2007.
Reuter P, Trautmann F. A report on global illicit drugs markets 1998-2007: full report. Brussel: European Communities; 2009.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Cocaine and crack cocaine: a growing public health issue. Lisbon: EMCDDA; 2007.
Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology. 2002;26(4):479–88.
Chen CY, Anthony JC. Epidemiological estimates of risk in the process of becoming dependent upon cocaine: cocaine hydrochloride powder versus crack cocaine. Psychopharmacology (Berl). 2004;172(1):78–86.
Hatsukami DK, Fischman MW. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality? JAMA. 1996;276(19):1580–8.
Hay G, Gannon M, MacDougall J, Millar T, Williams K, Eastwood C, et al. National and regional estimates of the prevalence of opiate use and/or crack cocaine use 2006/07: a summary of key findings: research report 9. London: Home Office; 2008.
McKetin R, McLaren J, Kelly E, Hall W, Hickman M. Estimating the number of regular and dependent methamphetamine users in Australia. Sydney: National Drug and Alcohol Research Centre; 2005.
Degenhardt L, Bruno R, Topp L. Is ecstasy a drug of dependence? Drug Alcohol Depend. 2009;107:1–10.
Wu LT, Ringwalt CL, Mannelli P, Patkar AA. Hallucinogen use disorders among adult users of MDMA and other hallucinogens. Am J Addict. 2008;17(5):354–63.
Cottler LB, Womack SB, Compton WM, Ben-Abdallah A. Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol. 2001;16(8):599–606.
Rogers G, Elston J, Garside R, Roome C, Taylor R, Younger P, et al. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess. 2009;13(6):3–4.
Peters GJY, Kok G, Schaalma HP. Careers in ecstasy use: do ecstasy users cease of their own accord? Implications for intervention development. BMC Public Health. 2008;8:376.
Blanken P, Hendriks VM, Van Ree JM, Van den Brink W. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction. 2010;105(2):300–8.
Uchtenhagen A. Heroin-assisted treatment in Switzerland: a case study in policy change. Addiction. 2010;105(1):29–37.
Gilson AM, Kreis PG. The burden of the nonmedical use of Âprescription opioid analgesics. Pain Med. 2009;10 Suppl 2:S89–100.
Hay G, Gannon M, MacDougall J, Millar T, Williams K, Eastwood C, et al. National and regional estimates of the prevalence of opiate use and/or crack cocaine use 2006/07: a summary of key findings. London: Home Office; 2008.
Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733–45.
Wiessing L, Van de Laar MJ, Donoghoe MC, Guarita B. HIV among injecting drug users in Europe: increasing trends in the East. Eurosurveillance. 2008;13(50):11.
Crofts N. Going where the epidemic is. Epidemiology and control of hepatitis C among injecting drug users. Aust Fam Phys. 2001;30(5):420–5.
Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352–8.
Brand DA, Saisana M, Rynn LA, Pennoni F, Lowenfels AB. Comparative analysis of alcohol control policies in 30 countries. PLOS Med. 2007;4:752–9.
Rehm J, Taylor B, Room R. Global burden of disease from alcohol, illicit drugs and tobacco. Drug Alcohol Rev. 2006;25(6):503–13.
Collins DJ, Lapsley HM. The costs of tobacco, alcohol and illicit drug abuse to Australian society in 2004/05: Summary version. Canberra: Commonwealth of Australia; 2008.
WHO. Evidence for the effectiveness and cost-effectiveness of interventions to reduce alcohol-related harm. Kopenhagen: WHO Regional Office for Europe; 2009.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
van Laar, M. (2012). Epidemiology of Alcohol and Drug Use. In: Verster, J., Brady, K., Galanter, M., Conrod, P. (eds) Drug Abuse and Addiction in Medical Illness. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3375-0_1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3375-0_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3374-3
Online ISBN: 978-1-4614-3375-0
eBook Packages: MedicineMedicine (R0)